The Canadian Psychiatric Research Foundation
In partnership with
AstraZeneca Canada Inc.
CIHR/Rx&D Collaborative Research Program
Institute of Neurosciences, Mental Health and Addiction
| Important Dates | |
| Opportunity Launched | September 2006 |
| Content Last Updated | (No updates since launch) |
| October 6, 2006 | Letter of Intent Deadline - Letter of Intent must be courier stamped by this date. |
| October 27, 2006 | Letter of Intent Decision. |
| November 24, 2006 | Full applications must be courier stamped by this date. |
| April 30, 2007 | Peer review will be completed by this date. |
| June 30, 2007 | Anticipated notification of decision. |
| August 1, 2007 | Anticipated start date. |
| Funds Available | |
CIHR's contribution to the amount available for this initiative is subject to availability of funds voted annually to CIHR by parliamentary appropriations, and the conditions that may be attached to them.
| |
| Summary | |
|
The goal of the Program is to promote meritorious research into the neurobiology of psychiatric disorders and addictions: schizophrenia, mood disorders (depression and bipolar disorders), anxiety disorders, and addiction and co-morbidity. | |
Partners
Objectives
Eligibility
Allowable Costs
Review Process and Evaluation Criteria
General CIHR Guidelines
Conditions of Funding
Communications Requirements
Monitoring, Performance Measurement and Evaluation
How to Apply
Contact Information
Description of Partners
The CIHR Research Translation Programs Branch is dedicated to identifying and developing collaborations with other CIHR institute(s), branch(es) or office(s), funding organizations and stakeholders to enhance the availability of funding for this strategic initiative, and to create, where appropriate, opportunities for knowledge exchange and translation related to the scope of this particular initiative. Applicants are invited to visit the Descriptions of Partners to find a list of partners and their respective mandates and/or strategic interests. This list will continue to evolve as new partners join in this initiative.
Based on available budget, funding will be provided for applications that are relevant to the research areas described above.
The goal of the Program is to promote meritorious research into the neurobiology of psychiatric disorders and addictions: schizophrenia, mood disorders (depression and bipolar disorders), anxiety disorders, and addiction and co-morbidity. Projects described can be basic research, preclinical research, clinical research, or translational research.
Eligibility criteria for all CIHR research funding programs apply. The business office of the institution of an eligible Nominated Principal Applicant generally administers CIHR funds. Please refer to the Eligibility Requirements for CIHR Grants and Awards regarding the eligibility requirements for individuals and institutions.
Randomized Controlled Trials (RCTs) will not be considered under this RFA.
Specific Eligibility Requirements
Eligibility requirements specific to this Request for Applications include the following:
Applicants should review the Tri-Agency (CIHR, NSERC and SSHRC) financial administration guidelines Use of Grant Funds for a complete listing and description of allowable costs and activities.
The full application must provide a detailed justification of all costs.
CPRF will be responsible for the distribution of CPRF funds to the host institution. CIHR will administer their funds and AZ funds directly to the host institution.
Relevancy Review
Prior to peer review, a relevancy review will be conducted on the Letters of Intent. CPRF, AZ, CIHR/Rx&D and INMHA will have access to anonymized project titles and summaries for this purpose.
The following criteria will be used in conducting the relevance review.
The review of applications for relevance to the strategic initiative will have no impact on the peer review process.
Peer Review
The quality of the peer review will be the joint responsibility of the Parties. CPRF's review process and its Peer Review Panel, in accordance with CIHR standards, will assess the scientific excellence of applications to this Program.
All applications will be peer reviewed by CPRF independent of the relevancy review results. The applications deemed meritorious will be considered for funding under this Program.
Upon completion of peer review, CIHR and AZ will receive the ranking list, merit scores (ratings) and recommendations of the peer review committee with regards to funding level and award term, for the submitted applications that fall in the fundable range and have been determined to be relevant to the specific research areas and objectives of the initiative. The list will be used for funding decision-making purposes and will remain anonymous.
In the event a researcher is not chosen for a partnered Neurobiology award, they may be considered for a CPRF award. If this is the case, CPRF will contact the researcher in question directly to discuss the matter.
This Request for Applications will follow the General Guidelines for Industry-Partnered Programs. Applicants are encouraged to demonstrate the use of Gender and Sex-Based Analysis in applications.
All conditions specified in CIHR General Grants and Awards Policies shall apply to applications funded through this Request for Applications. Conditions cover areas such as Applicant and Institutional Responsibilities, Ethics, Official language policy, Access to Information and Privacy Acts, and Acknowledgement of CIHR Support. Successful applicants will be informed of any special financial conditions prior to the release of funds or when they receive CIHR's Authorization for Funding (AFF) document.
In addition to CIHR standard guidelines and requirements, the following special conditions shall apply:
Grantees will be required to provide CPRF with progress and financial reports on the first year of the project and final progress and financial reports at the end of the grant. Year 1 Progress Reports must be submitted by March 31, 2008. Funding for the second year is conditional on satisfactory review of the progress report. In addition, a Final Report must be submitted three (3) months following termination of the grant. Reports should be at least 1,000 words in length and must describe the aims of the research, the methods used, and the results obtained. All papers and abstracts related to the funded research that are published or in press must be appended to the reports. CPRF will collect and distribute copies of the reports to the other Parties.
Interaction of Grantees with AZ: Grantees may be invited by a representative of the AZ research staff, within twelve months of accepting the grant, to visit AZ R&D-CNS in Wilmington, Delaware, USA, at the company's expense. During the visit, the grantee will deliver a seminar describing the current status of the approved research project. This visit will also provide an opportunity for the grantee to interact with AZ scientists, gain exposure to the range of technologies that exist within AZ, and explore mutual research interests and potential collaborations. Any future collaborative interactions will occur only by mutual agreement between the grantee and members of the scientific staff at AZ. There will be no requirement for collaborative interactions as a condition of funding.
Access to Information Act and Privacy Act, and the Personal Information Protection and Electronic Documents Act (PIPEDA)
All personal information collected by CIHR about applicants is used to review applications, to recruit reviewers, to administer and monitor grants and awards, to compile statistics, and to promote and support health research in Canada. Consistent with these purposes, applicants should also expect that information collected by CIHR may be shared as described in Use and Disclosure of Personal Information Provided to CIHR for Peer Review.
CIHR as a federal entity is subject to the Access to Information Act and the Privacy Act, therefore the requirements of these two statutes will apply to all information located in CIHR's premises including, without limitation, cost-sharing agreements related to this Request for Applications and all matters pertaining thereto.
While respecting the application of the Privacy Act to federal entities, all signing parties involved in a collaborative agreement will also be bound by the Personal Information Protection and Electronic Documents Act (PIPEDA). All personal information (as identified by the PIPEDA) collected, used or disclosed in the course of any commercial activity under collaborative agreements related to the Request for Applications will be collected, used and disclosed in compliance with the PIPEDA.
Grant recipients are required to acknowledge CIHR, its institutes and partners in any communication or publication related to the project. See CIHR General Grants and Awards Policies, Acknowledgement of CIHR's Support for details on CIHR's communication requirements. The contributing institutes / partners will be identified on the Authorization for Funding and decision letter.
Research dissemination and commercialization: All Partners shall receive copies of manuscripts upon acceptance for publication, and conference presentations, which arise during or result from the funded project.
The Parties expect to be informed immediately of any commercial exploitation arising from activity supported through the Program.
CPRF, INMHA, CIHR Rx&D, and AZ do not and will not claim any proprietary right to any intellectual or tangible property resulting from the research grants made under the agreement.
The grantee's host institution (university or hospital) will be expected to have a clear policy regarding the grantee's right to publish and intellectual property, in order to provide adequate protection and management of intellectual property of potential commercial interest. The onus is on the grantee to seek patent protection in collaboration with the host institution for inventions or developments arising from research supported under this Program.
INHMA and CIHR Rx&D directs that the grantee and his or her host institution make every reasonable effort to maximize beneficial impact to Canada from the exploitation of the knowledge and intellectual property resulting from the research supported under this Program.
The above statements on proprietary rights will be included in the notification of grant letter.
CPRF and CIHR committed to demonstrating results to Canadians for the money invested in health research. Therefore, processes for monitoring progress and appropriate use of funds, as well as for performance measurement and program evaluation are in place. As a result, funding recipients must:
The application process is comprised of two steps: Letter of Intent and Full Application.
Please note that, upon consent of the applicant, copies of applications will be shared with partners for administrative purposes.
1) Letter of Intent (LOI)
The Letter of Intent is comprised of:
i) CIHR Research Module:
The Research Module must be completed using the CIHR Webforms.
ii) Letter
The letter itself must not exceed three (3) pages and must address the following:
Research program and relevancy: Describe the project and justify why it is responsive to this Request for Applications, including a brief description of the:
Principal Applicant(s): Justify the leadership capacity of the individual(s) identified as the Principal Applicant(s).
iii) Attachments
Applicants are advised to follow the Acceptable Application Module Formats which outline formatting requirements for attachments.
Submit one original and six copies of the Letter of Intent to the address below, by the deadline date indicated at the beginning of this Request for Applications.
Applicants that successfully pass the relevancy review will receive an invitation to submit a full application.
2) Full Application
Review the application instructions provided in How to Apply for Funding.
Select "Operating Grants - Industry Partnered" (Registration and Application) from the Grant Programs Application Packages.
Additional instructions must be followed for this RFA:
Submit one original and eight copies of the full application to the address below, by the deadline date indicated at the beginning of this Request for Applications.
Send Letters of Intent and Full Applications by Courier to:
RE: "Neurobiology of Psychiatric Disorders and Addictions Program"
Canadian Psychiatric Research Foundation
133 Richmond Street West, Suite 200
Toronto, ON
M5H 2L3
For questions on how to apply, and the peer review process contact
Grants Officer
Canadian Psychiatric Research Foundation
Telephone: (416) 351-7757 ext 23
Fax: (416) 351-7765
E-mail: admin@cprf.ca
For questions about this initiative and research objectives contact:
Joan Montgomery
Executive Director
Canadian Psychiatric Research Foundation
133 Richmond Street West, Suite 200
Toronto, ON M5H 2L3
Telephone: 416-351-7757, Ext. 25
Fax: 416-351-7765
E-mail: jmontgomery@cprf.ca
Web: www.cprf.ca
For questions on CIHR funding guidelines:
Melody Sajedi
Program Delivery Officer
Canadian Institutes of Health Research
Telephone: (613) 957-1188
Fax: (613) 954-1800
E-mail: msajedi@cihr-irsc.gc.ca
Canadian Psychiatric Research Foundation (CPRF)
CPRF is a nation-wide, non-profit organization established in 1980 to raise and distribute funds for psychiatric research in Canadian universities and teaching hospitals. The Foundation also publishes a series of handbooks on mental disorders to bring the information from research to the community.
AstraZeneca Canada Inc. (AZ)
AZ is an international pharmaceutical company with a strong research base and product portfolio designed to fight disease in seven areas of medical need including the central nervous system (CNS). The company's CNS research portfolio is focused on the areas of chronic pain management and both neurologic and psychiatric disease. AZ Canada Inc. is involved in CNS as a partner with Canadian academic researchers. The Psychiatric disorders research efforts are mainly conducted at AZ R&D, Wilmington, USA.
Canadian Institutes of Health Research (CIHR)
CIHR is Canada's major federal funding agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.
CIHR/Rx&D; Collaborative Research Program (CIHR/Rx&D;)
CIHR/Rx&D; is a partnership between Canada's Research-Based Pharmaceutical Companies (Rx&D;) and CIHR established to provide an opportunity for health researchers to work in collaboration with Rx&D; companies. The Program enables scientists, clinicians and members of the full spectrum of health professions, and Rx&D; members to optimize opportunities in clinical research benefiting the health of Canadians.
